These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32757851)

  • 1. A guided approach to preclinical bioanalysis of proteins using immunoassays for pharmacokinetic and pharmacodynamic assessments.
    Eangoor P
    Bioanalysis; 2020 Aug; 12(16):1105-1110. PubMed ID: 32757851
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of homogeneous proximity immunoassays for preclinical bioanalysis.
    Eangoor P; Das S; Pucci V
    Bioanalysis; 2020 Dec; 12(24):1757-1766. PubMed ID: 33259228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis.
    Roman J; Qiu J; Dornadula G; Hamuro L; Bakhtiar R; Verch T
    J Pharmacol Toxicol Methods; 2011; 63(3):227-35. PubMed ID: 21147239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risks of drug screening using immunoassays].
    Schütz H; Verhoff MA; Risse M; Auch J; Weiler G
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1931-4. PubMed ID: 15372373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of multiplexed pharmacokinetic immunoassay to quantify
    Woodbury N; Bald E; Geist B; Yang TY
    Bioanalysis; 2019 Dec; 11(24):2251-2268. PubMed ID: 31845605
    [No Abstract]   [Full Text] [Related]  

  • 7. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic studies in drug product development.
    Meibohm B; Derendorf H
    J Pharm Sci; 2002 Jan; 91(1):18-31. PubMed ID: 11782894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incurred sample reproducibility and stability assessment in a cell-based drug concentration assay.
    White JT; Crossman M; Subramanyam M
    Bioanalysis; 2015; 7(11):1347-53. PubMed ID: 26110707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdialysis: a technique for pharmacokinetic-pharmacodynamic studies of oncological drugs.
    Wei YH; Xu LZ; Shen Q; Li FZ
    Curr Pharm Biotechnol; 2009 Sep; 10(6):631-40. PubMed ID: 19619119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate--SAR566658--for pharmacokinetic interpretation improvement.
    Pascual MH; Verdier P; Malette P; Mnich J; Ozoux ML
    J Immunol Methods; 2013 Oct; 396(1-2):140-6. PubMed ID: 23892158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AlphaLISA immunoassay platform- the "no-wash" high-throughput alternative to ELISA.
    Bielefeld-Sevigny M
    Assay Drug Dev Technol; 2009 Feb; 7(1):90-2. PubMed ID: 19382891
    [No Abstract]   [Full Text] [Related]  

  • 14. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
    Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods.
    Bowsher RR; Nowatzke WL
    Bioanalysis; 2011 Apr; 3(8):883-98. PubMed ID: 21510762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development.
    Sternebring O; Alifrangis L; Christensen TF; Ji H; Hegelund AC; Högerkorp CM
    Cytometry B Clin Cytom; 2016 Mar; 90(2):220-9. PubMed ID: 26205127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation.
    Germani M; Del Bene F; Rocchetti M; Van Der Graaf PH
    Comput Methods Programs Biomed; 2013 May; 110(2):203-14. PubMed ID: 23182621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).
    Neubert H; Olah T; Lee A; Fraser S; Dodge R; Laterza O; Szapacs M; Alley SC; Saad OM; Amur S; Chen L; Cherry E; Cho SJ; Cludts I; Donato LD; Edmison A; Ferrari L; Garofolo F; Haidar S; Hopper S; Hottenstein S; Ishii-Watabe A; Kassim S; Kurki P; Lima Santos GM; Miscoria G; Palandra J; Pedras-Vasconcelos J; Piccoli S; Rogstad S; Saito Y; Savoie N; Sikorski T; Spitz S; Staelens L; Verthelyi D; Vinter S; Wadhwa M; Wang YM; Welink J; Weng N; Whale E; Woolf E; Wu J; Yan H; Yu H; Zhou S
    Bioanalysis; 2018 Dec; 10(23):1897-1917. PubMed ID: 30488729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in selectivity, specificity and quantitation range of ligand-binding assays: case studies using a microfluidics platform.
    Yang TY; Uhlinger DJ; Ayers SA; O'Hara DM; Joyce AP
    Bioanalysis; 2014 Apr; 6(8):1049-57. PubMed ID: 24830889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioanalysis of recombinant proteins and antibodies by mass spectrometry.
    Ezan E; Dubois M; Becher F
    Analyst; 2009 May; 134(5):825-34. PubMed ID: 19381370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.